Sialidase 1 targeting therapeutics - Collaborations Pharmaceuticals
Latest Information Update: 28 Jul 2025
At a glance
- Originator Collaborations Pharmaceuticals
- Class Small molecules
- Mechanism of Action Neuraminidase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Lysosomal storage diseases
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for preclinical development in Lysosomal storage diseases in USA
- 21 Feb 2022 Sialidosis therapeutics - Collaborations Pharmaceuticals is available for licensing as of 07 Feb 2022. https://www.collaborationspharma.com/how-we-collaborate
- 07 Feb 2022 Collaborations Pharmaceuticals has patent pending for sialidosis before February 2022 (Collaborations Pharmaceuticals pipeline, February 2022)